de Weger VS, et al. - Authors here assessed the potential drug–drug interaction of dovitinib with the CYP1A2 inhibitor fluvoxamine in patients with advanced solid tumors. Findings suggested an increase in exposure to dovitinib with fluvoxamine co-administration. Thereby suggesting a risk of dovitinib related toxicity among patients. Therefore, they recommended not to co-administer dovitinib with moderate and strong CYP1A2 inhibitors, without dose reduction.